The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT03910569
Status
Recruiting
Apply to this trial

Conditions

  • Takotsubo Cardiomyopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.

Key Dates

Start date
Feb 1, 2019
Status verified
Aug 2025
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Number of participants with Prevalence of the Takotsubo [ Time Frame: Baseline, Annual follow-up up to 30years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars Sinai Medical CenterLos AngelesCalifornia90005
Jenna Maughan

Find similar trials in Los Angeles, CA

By research site
Cedars Sinai Medical Center· Los Angeles, CA

Related Studies